NCT04920708
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04920708
Title Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)
Acronym FAIM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Royal Marsden NHS Foundation Trust
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
Addenbrookes Hospital Cambridge Cambridgeshire CB2 0QQ United Kingdom Details
Royal Cornwall Hospital Truro Cornwall TR1 3LQ United Kingdom Details
Mount Vernon Cancer Centre London Surrey HA6 2RN United Kingdom Details
Velindre Cancer Centre Cardiff Wales CF14 2TL United Kingdom Details
Western General Hospital Edinburgh EH4 2XU United Kingdom Details
Beatson West of Scotland Cancer Centre Glasgow United Kingdom Details
Royal Free Hospital London NW3 2QC United Kingdom Details
Royal Marsden NHS Foundation Trust London SW3 6JJ United Kingdom Details
Imperial College University Hospitals NHS Trust London W2 1NY United Kingdom Details
University College London Hospital London United Kingdom Details
The Christie NHS Foundation Trust Manchester M20 4BX United Kingdom Details
Nottingham City Hospital Nottingham United Kingdom Details
Oxford University Hospitals Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field